Compare AstraZeneca plc (AZN) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs WD 40 Company — how do they compare? AstraZeneca plc trades at $158.64 (market cap $248.14B), while WD 40 Company trades at $232.42 (market cap $3.13B). The key difference: AstraZeneca plc is far larger — about 79.3× WD 40 Company's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | WDFC | |
|---|---|---|
Market Cap | $248.14B | $3.13B |
Sector | Health | Technology |
52-Week High | $209.48 | $264.91 |
52-Week Low | $147.06 | $187.52 |
Enterprise Value | $275.41B | $3.18B |
Dividend Yield | 2.01% | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
WDFC trades at $232.3, down 0.94% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $2.33 per share, beating estimates, but faces gross margin pressure from input costs. Revenue grew to $675 million in 2026, though net income slightly declined to $89 million. A dividend of $1.02 per share is scheduled for payment on July 31, 2026.
The outlook is mixed: solid brand strength and cash flow support stability, but high valuation (P/E 35.39) and margin pressures pose risks. Analyst sentiment is cautious with a hold-heavy consensus. Key opportunities include global market penetration, while risks involve cost inflation and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
